|
15 Jul 2026 |
Jyothy Labs
|
Consensus Share Price Target
|
200.28 |
268.82 |
- |
34.22 |
buy
|
|
|
|
|
31 Jan 2025
|
Jyothy Labs
|
Sharekhan
|
200.28
|
490.00
|
398.40
(-49.73%)
|
|
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q3FY25 performance was muted with revenue growing by just 4%, while a ~110 bps y-o-y decline in OPM led to 4% y-o-y decline in PAT.
|
|
04 Dec 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
200.28
|
496.00
|
411.15
(-51.29%)
|
|
Buy
|
|
|
|
|
13 Nov 2024
|
Jyothy Labs
|
Axis Direct
|
200.28
|
500.00
|
436.10
(-54.07%)
|
|
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
12 Nov 2024
|
Jyothy Labs
|
Motilal Oswal
|
200.28
|
500.00
|
441.35
(-54.62%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported flat sales YoY (miss) in 2QFY25. It posted a five-year CAGR of 10%. Volume growth was at 3%, on account of a high base.
|
|
12 Nov 2024
|
Jyothy Labs
|
Sharekhan
|
200.28
|
575.00
|
441.35
(-54.62%)
|
|
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q2FY2025 performance was muted with revenue and PAT remaining flat y-o-y. OPM at 18.9% rose by 38 bps y-o-y.
|
|
13 Aug 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
200.28
|
645.00
|
548.10
(-63.46%)
|
|
Accumulate
|
|
|
|
|
26 Jul 2024
|
Jyothy Labs
|
Axis Direct
|
200.28
|
600.00
|
548.45
(-63.48%)
|
|
Buy
|
|
|
We maintain our long-term BUY rating on the stock.
|
|
25 Jul 2024
|
Jyothy Labs
|
Sharekhan
|
200.28
|
655.00
|
547.70
(-63.43%)
|
|
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q1FY2025 operating performance was in line with our expectation with revenues growing by 8% (versus expectation of 8.5%) while OPM stood at 18% (versus expectation of 17.9%).
|
|
25 Jul 2024
|
Jyothy Labs
|
ICICI Securities Limited
|
200.28
|
640.00
|
547.70
(-63.43%)
|
|
Buy
|
|
|
JYL’s Q1FY25 volume growth of 11% YoY is a material outperformance vs peers on a higher base as it continues to focus on direct distribution expansion, innovation, new SKUs coupled with continued investment behind the brands.
|
|
25 Jul 2024
|
Jyothy Labs
|
Motilal Oswal
|
200.28
|
565.00
|
547.70
(-63.43%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported a revenue growth of 8% YoY (in line) in 1QFY25. It delivered a volume growth of 11% and continued to focus on volume-led growth to gain market share across categories.
|